Overview

Antibody Drug Conjugate Market is poised to value USD 16820.81 million by 2028 end at a CAGR of 16.4% during the forecast period 2022 to 2028.

Name: Hydroxyapatite Market: Industry Trends, Share, Size and Forecast
Brand: FutureWise Research
Price: 25.99 USD
Rating: 4.7 (43 reviews)

Antibody drug conjugates consist of three main components: an antibody specific to the target antigen, an antigen with a restricted expression on normal cells, a cytotoxic agent designed to kill target cancer cells, and a chemical linker for attaching the cytotoxic agent to the antibody. In addition to their therapeutic potential, antibody-drug conjugates pose both technical and developmental challenges. The use of antibody-drug conjugates is considered to be the new wave of therapeutic agents. These drugs combine monoclonal antibody targeting abilities with cytotoxic drugs' ability to kill specific cells. Technology advancements have led to the success of this technology. The new class of therapeutic agents, antibody-drug conjugates, is becoming increasingly popular among both large and small pharmaceutical companies. Despite being used for treating acute myelogenous leukemia, a clinical trial found the drug only increased mortality rates and provided no benefit over conventional therapies. Thus, only two antibody drug conjugates are approved in the market. Technological advancements will drive the global demand for antibody-drug conjugates. The increasing prevalence of cancer, the increasing aging population, and the increase in obesity are driving the market. The growing number of antibody-drug conjugates research activities, preclinical research, and research on advanced drug discoveries, together with growing collaboration between research institutes, biotechnology companies, and pharmaceutical companies, is also driving the market. Despite the recent growth in antibody-drug conjugates technology, the number of companies developing these methods has not changed significantly. It is expected that pharmaceutical and biotechnology companies will increase their investment in the market.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Antibody Drug Conjugate Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Antibody Drug Conjugate Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Antibody Drug Conjugate Market:
• Seattle Genetics
• ImmunoGen, Inc.
• Roche Holding AG
• Genentech
• Concortis Biotherapeutics
• AGENSYS, INC.
• Antikor
• Immunomedics
• Pfizer Inc.
• Celldex Therapeutics
• Millennium Pharmaceuticals
• AbbVie Inc.
• Bayer HealthCare
• Astellas Pharma/Agensys
• Progenics Pharmaceuticals
• Mersana Therapeutics
• Synthon
• Heidelberg Pharma
• Oxford BioTherapeutics
(Note: The list of the major players will be updated with the latest market scenario and trends)

Antibody Drug Conjugate Market Segmentation:
By Type
• Monoclonal Antibodies
• Linker
• Drug/Toxin
• Others
By Application
• Leukemia
o Acute Myeloid Leukemia (AML)
o Chronic Myeloid Leukemia (CML)
o Acute Lymphocytic Leukemia (ALL)
o Chronic Lymphocytic Leukemia (CLL)
• Prostate Cancer
• Kidney Cancer
• Pancreas Cancer
• Ovary Cancer
• Glioblastoma
• Lung Cancer
• Colon Cancer
• Breast Cancer
• Skin Cancer
• Solid Tumors
• Multiple Myeloma
• Lymphoma
By Product
• Adcertis
• Kadcyla
• Others
By Technology
• ImmunoGen Technology
• Seattle Genetics Technology
• Immunomedics Technology
• Others
By End User
• Hospitals
• Specialized Cancer Centers
• Academic Research Institutes
• Biopharmaceutical Companies
• Others
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Antibody Drug Conjugate Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Antibody Drug Conjugate Market By Type, By Application, By Product, By Technology, By End User and By Region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com